AstraZeneca PLC (UK) Today
| AZN Stock | 10,612 18.00 0.17% |
Performance0 of 100
| Odds Of DistressLess than 34
|
AstraZeneca PLC is trading at 10612.00 as of the 30th of November 2024, a 0.17 percent increase since the beginning of the trading day. The stock's lowest day price was 10532.0. AstraZeneca PLC has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for AstraZeneca PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of May 1993 | Category Healthcare | Classification Health Care |
AstraZeneca PLC is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 1.55 B outstanding shares. More on AstraZeneca PLC
Moving together with AstraZeneca Stock
Moving against AstraZeneca Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
AstraZeneca Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. AstraZeneca PLC's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding AstraZeneca PLC or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, AstraZeneca PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AstraZeneca PLC's managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
| Executive VicePresident | Menelas Pangalos | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
| Excise Tax Activities | Animal TestingCatholic | ||||
AstraZeneca PLC's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to AstraZeneca PLC's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsAstraZeneca PLC can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AstraZeneca PLC's financial leverage. It provides some insight into what part of AstraZeneca PLC's total assets is financed by creditors.
| |||||
AstraZeneca PLC (AZN) is traded on London Exchange in UK and employs 89,900 people. AstraZeneca PLC is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 164.52 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AstraZeneca PLC's market, we take the total number of its shares issued and multiply it by AstraZeneca PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AstraZeneca PLC operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.55 B outstanding shares.
AstraZeneca PLC generates positive cash flow from operations, but has no cash available
Check AstraZeneca PLC Probability Of Bankruptcy
Ownership AllocationAstraZeneca PLC holds a total of 1.55 Billion outstanding shares. Over half of AstraZeneca PLC's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in AstraZeneca PLC. Please watch out for any change in the institutional holdings of AstraZeneca PLC as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AstraZeneca Ownership Details
AstraZeneca PLC Risk Profiles
Although AstraZeneca PLC's alpha and beta are two of the key measurements used to evaluate AstraZeneca PLC's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.1 | |||
| Standard Deviation | 1.65 | |||
| Variance | 2.71 | |||
| Risk Adjusted Performance | (0.15) |
AstraZeneca Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in AstraZeneca PLC without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
AstraZeneca PLC Corporate Management
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer | CEO Officer | Profile | |
| Pam Cheng | EVP Board | Profile | |
| MBA DVM | CEO Director | Profile | |
| Aradhana MD | CFO Director | Profile | |
| Katarina Ageborg | Chief Sustainability | Profile | |
| Jeffrey Pott | Chief CHRO | Profile | |
| Ruud Dobber | Executive Unit | Profile |
Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.